BRPI0519562A2 - construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea - Google Patents

construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea

Info

Publication number
BRPI0519562A2
BRPI0519562A2 BRPI0519562-4A BRPI0519562A BRPI0519562A2 BR PI0519562 A2 BRPI0519562 A2 BR PI0519562A2 BR PI0519562 A BRPI0519562 A BR PI0519562A BR PI0519562 A2 BRPI0519562 A2 BR PI0519562A2
Authority
BR
Brazil
Prior art keywords
fviii
proteinaceous construct
vwf
complex
life
Prior art date
Application number
BRPI0519562-4A
Other languages
English (en)
Inventor
Friedrich Scheiflinger
Peter Turecek
Juergen Siekmann
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0519562A2 publication Critical patent/BRPI0519562A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Abstract

CONSTRUÇçO PROTEINÁCEA, COMPLEXO, MÉTODO PARA PROLONGAR A MEIA-VIDA IN VIVO DE FATOR VIII (FVIII) OU UM DERIVADO BIOLOGICAMENTE ATIVO DO MESMO COMPOSIÇçO FARMACÊUTICA, E, MÉTODO PARA FORMAR UMA CONSTRUÇçO PROTEINÁCEA. A presente invenção refere-se a uma construção proteinácea (também denominada conjugado polímero-VWF) compreendendo fator de von Willebrand (VWF) plasmático e/ou recombinante, sendo que referido VWF é ligado a pelo menos uma molécula e também a um complexo de referida construção proteinácea e pelo menos uma proteína de fator VIII (FVIII). A molécula de polímero fisiologicamente aceitável pode ser, por exemplo, polietileno glicol (PEG) ou ácido polissiálico (PSA). Adicionalmente, a presente invenção refere-se a métodos para prolongar a meia-vida in vivo de VWF ou FVIII no sangue de um mamífero apresentando um distúrbio de sangramento associado com defeitos funcionais de, ou deficiências de pelo menos um de FVIII ou VWF.
BRPI0519562-4A 2004-12-27 2005-12-23 construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea BRPI0519562A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63924404P 2004-12-27 2004-12-27
US66837805P 2005-04-04 2005-04-04
US67190105P 2005-04-15 2005-04-15
US68508605P 2005-05-26 2005-05-26
PCT/US2005/046879 WO2006071801A2 (en) 2004-12-27 2005-12-23 Polymer-von willebrand factor-conjugates

Publications (1)

Publication Number Publication Date
BRPI0519562A2 true BRPI0519562A2 (pt) 2009-01-27

Family

ID=36540284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519562-4A BRPI0519562A2 (pt) 2004-12-27 2005-12-23 construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea

Country Status (16)

Country Link
US (4) US7884075B2 (pt)
EP (1) EP1835938B1 (pt)
JP (2) JP5022231B2 (pt)
KR (1) KR20070092754A (pt)
CN (1) CN101163506B (pt)
AU (1) AU2005322067B8 (pt)
BR (1) BRPI0519562A2 (pt)
CA (1) CA2591852A1 (pt)
DK (1) DK1835938T3 (pt)
ES (1) ES2434035T3 (pt)
HK (1) HK1105276A1 (pt)
IL (1) IL183634A (pt)
MX (1) MX2007007877A (pt)
PL (1) PL1835938T3 (pt)
PT (1) PT1835938E (pt)
WO (1) WO2006071801A2 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
CN101163506B (zh) 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
CN101557830B (zh) * 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
CN101679496B (zh) * 2007-05-18 2013-03-13 巴克斯特国际公司 用于由vwf前肽制备成熟vwf的方法
US9107902B2 (en) * 2007-06-13 2015-08-18 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
WO2009000522A1 (en) * 2007-06-26 2008-12-31 Baxter International Inc. Hydrolysable polymeric fmoc-linker
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
BRPI0821700A2 (pt) 2007-12-27 2015-06-16 Baxter Int Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução
CA2709073A1 (en) * 2007-12-27 2009-07-09 Baxter International Inc. Methods for differentiating plasma-derived protein from recombinant protein in a sample
CA2710762A1 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AR070089A1 (es) * 2007-12-31 2010-03-10 Baxter Int Animales no humanos transgenicos que expresan factores de la coagula-cion sanguinea humanos y usos de los mismos
JP2011519898A (ja) * 2008-05-06 2011-07-14 オクタファルマ・アーゲー 複合体
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
BRPI0916326A2 (pt) * 2008-07-23 2020-08-25 Hanmi Holdings Co., Ltd. complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
MX2011004085A (es) * 2008-10-17 2011-09-27 Baxter International Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
CA2741209C (en) * 2008-10-20 2016-12-20 Usv Limited An improved process for pegylation of proteins
PL2349314T3 (pl) * 2008-10-21 2013-07-31 Baxalta Inc Formulacje liofilizowanego rekombinowanego VWF
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
PL2356467T3 (pl) * 2008-12-11 2013-12-31 Baxalta Inc Wykrywanie fizjologicznie dopuszczalnych cząsteczek polimeru z zastosowaniem spektroskopii w bliskiej podczerwieni
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
HUE028056T2 (en) * 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
EP2462231A2 (en) 2009-08-04 2012-06-13 Baxter International Inc Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
ES2562256T5 (es) * 2009-08-20 2023-07-20 Takeda Pharmaceuticals Co Purificación de FVW para aumentar la eliminación de virus sin envoltura lipídica
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
NZ600278A (en) 2009-11-13 2014-04-30 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP4023247A1 (en) 2010-07-30 2022-07-06 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
KR101309566B1 (ko) 2010-12-10 2013-09-17 포항공과대학교 산학협력단 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
US20120329127A1 (en) 2011-05-27 2012-12-27 Baxter Healthcare S.A. Therapeutic proteins with increased half-life and methods of preparing same
CA2838845C (en) * 2011-06-10 2019-08-06 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
MX357403B (es) * 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Polipeptidos de factor viii quimericos y usos de los mismos.
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
DK2882450T3 (da) * 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EP3875106A1 (en) * 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN106456718A (zh) * 2014-01-10 2017-02-22 比奥根Ma公司 因子viii嵌合蛋白及其用途
DK3158055T3 (da) 2014-06-13 2019-10-14 Csl Ltd Forbedret produktion af recombinant von willebrand-faktor i en bioreaktor
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
CN104491917B (zh) * 2014-12-30 2018-01-09 广州市拜特凇医药科技有限公司 一种含有peg或其衍生物的生物材料
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
WO2016188905A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｆｖｉｉｉ因子ポリマー結合体
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
WO2018087267A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
SG10201912768YA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
CN111565741A (zh) 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
AU2018321131A1 (en) 2017-08-23 2020-04-09 Csl Behring Gmbh Method for virus filtration of von Willebrand Factor
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第ｆｖｉｉｉ因子ポリマー結合体
EP3768697A1 (en) 2018-03-21 2021-01-27 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
CA3128498A1 (en) 2019-02-01 2020-08-06 Bjorn Mellgard Methods of prophylactic treatment using recombinant vwf (rvwf)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
AU2297792A (en) * 1991-06-28 1993-01-25 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic polypeptides based on von willebrand factor
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
SK282483B6 (sk) * 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6127153A (en) * 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AT405740B (de) 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
DK0985697T3 (da) * 1998-03-24 2006-05-15 Nof Corp Oxiranderivater og fremgangsmåde til fremstilling deraf
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
AU6357900A (en) * 1999-07-20 2001-02-05 Amgen, Inc. Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
SE515295C2 (sv) * 1999-11-23 2001-07-09 Medicarb Ab Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat
AUPR610501A0 (en) 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
AU2004215912B2 (en) * 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
WO2005032581A2 (en) * 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
CN1913925A (zh) * 2003-12-10 2007-02-14 尼克塔治疗亚拉巴马公司 含有两组不同聚合物－活性剂缀合物的组合物
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物

Also Published As

Publication number Publication date
HK1105276A1 (en) 2008-02-06
CN101163506A (zh) 2008-04-16
AU2005322067B2 (en) 2012-07-05
PT1835938E (pt) 2013-11-06
KR20070092754A (ko) 2007-09-13
EP1835938A2 (en) 2007-09-26
AU2005322067B8 (en) 2012-07-26
IL183634A (en) 2012-02-29
US20130190242A1 (en) 2013-07-25
US20120135462A1 (en) 2012-05-31
US7884075B2 (en) 2011-02-08
WO2006071801A2 (en) 2006-07-06
JP2008525491A (ja) 2008-07-17
PL1835938T3 (pl) 2014-01-31
US20060160948A1 (en) 2006-07-20
DK1835938T3 (da) 2013-11-04
US8357779B2 (en) 2013-01-22
JP2012126750A (ja) 2012-07-05
AU2005322067A1 (en) 2006-07-06
IL183634A0 (en) 2007-09-20
US20110111455A1 (en) 2011-05-12
EP1835938B1 (en) 2013-08-07
CN101163506B (zh) 2012-09-26
WO2006071801A3 (en) 2007-08-16
MX2007007877A (es) 2007-08-21
JP5715983B2 (ja) 2015-05-13
JP5022231B2 (ja) 2012-09-12
US8076463B2 (en) 2011-12-13
US8835388B2 (en) 2014-09-16
CA2591852A1 (en) 2006-07-06
ES2434035T3 (es) 2013-12-13

Similar Documents

Publication Publication Date Title
BRPI0519562A2 (pt) construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
ES2451651T3 (es) Composiciones de liberación inmediata para el tratamiento de daños tisulares
JP2008525491A5 (pt)
BRPI0720282B8 (pt) construção proteica, composição farmacêutica, e, kit
Lorentz et al. Engineered aprotinin for improved stability of fibrin biomaterials
ES2720368T3 (es) Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
RU2008145084A (ru) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
DK2717905T3 (en) TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
EP2130549B1 (en) Solid fibrinogen preparation
CO6230995A2 (es) Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
PT2440239T (pt) Composições de hemoglobina
DE602005019853D1 (de) Pharmazeutische Zusammensetzung mit lyophilisiertem rekombinantem Faktor VIII ohne Albumin als Stabilisator
Nam et al. Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration
CN107249622A (zh) 包含纤溶酶原的药物组合物和其用途
PT1559431E (pt) Composição farmacêutica para derivados peptídicos de trombina.
DE50110182D1 (de) Verwendung von fibrin/fibrinogenpeptiden und -proteinen zur herstellung eines arzneimittels
ES2331970T3 (es) Procedimiento para determinar el efecto antiinflamatorio de un peptido.
US20210299158A1 (en) Heparin Conjugated to Collagen-Binding Peptides for Targeting to Biological and Synthetic Tissues
US20200289416A1 (en) Drug delivery vehicles for atherosclerosis nanomedicine
Cattaneo et al. Desmopressin (DDAVP)
CY1114581T1 (el) Συζευγματα πολυμερους - παραγοντα von willebrand
Jeimy et al. Location of the multimerin 1 binding site in coagulation factor V: an update

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B25G Requested change of headquarter approved

Owner name: BAXTER INTERNATIONAL INC (US) , BAXTER HEALTHCARE

Free format text: ENDERECO DO 2O DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110115944/RJ DE 11/11/2011.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/755 (2006.01), A61K 47/60 (2017.01), C07K